{"id":"W1991039961","doi":"10.1097/01.jto.0000283406.00250.d4","title":"PD3-2-4: Third-line erlotinib therapy versus best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC), Canada. Is it cost effective?","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Oncology; Cost effectiveness; Internal medicine; Docetaxel; Clinical endpoint; Life expectancy; Cancer; Epidermal growth factor receptor; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001468562,0.0003199409,0.001106014,0.0003901084,0.0004565724,0.001160167,0.0011011,0.0009418596,0.004141314],"category_scores_gemma":[0.004460909,0.0001745478,0.0009384701,0.0008490984,0.0004778507,0.0005202665,0.0006171645,0.001423027,0.000182726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0215184,"about_ca_system_score_gemma":0.02136981,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.7751859,"about_ca_topic_score_gemma":0.8966647,"domain_scores_codex":[0.9992711,0.000293748,0.00004430953,0.00004452017,0.0001184695,0.0002277761],"domain_scores_gemma":[0.9982375,0.0003746227,0.0002361711,0.00002733571,0.0002256225,0.0008987495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2270809,0.003549706,0.1513293,0.001623966,0.002621747,0.0007909645,0.0004404598,0.07119665,0.001332432,0.003135323,0.05550787,0.4813907],"study_design_scores_gemma":[0.04704854,0.02507012,0.7585654,0.001352017,0.01091103,0.0009617211,0.002880089,0.1158021,0.002272703,0.003963741,0.03088816,0.0002842659],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9601087,0.01285473,0.0004182865,0.01500296,0.0002849663,0.0002604189,0.003506722,0.00006110409,0.007502125],"genre_scores_gemma":[0.9951918,0.00206368,0.0002507616,0.0005638681,0.00005964061,0.0000235654,0.0006921656,0.000006306183,0.001148198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2248141,"threshold_uncertainty_score":0.4522762,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02479143580895509,"score_gpt":0.3453572376271947,"score_spread":0.3205658018182396,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}